Mark Jacobson Sells 233 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 233 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total transaction of $53,165.94. Following the completion of the sale, the chief operating officer owned 4,517 shares in the company, valued at $1,030,689.06. This represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $222.63 on Thursday. Axsome Therapeutics, Inc. has a 1 year low of $96.09 and a 1 year high of $234.29. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.48. The stock has a market capitalization of $11.46 billion, a PE ratio of -59.69 and a beta of 0.59. The company’s 50 day simple moving average is $172.69 and its two-hundred day simple moving average is $164.03.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The firm had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The company’s revenue was up 57.4% on a year-over-year basis. Analysts predict that Axsome Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Strong commercial traction — Axsome reported Q1 product revenue of $191.2M, up ~57% year‑over‑year driven by AUVELITY and SUNOSI, which supports the company’s growth narrative and near‑term cash generation. Read More.
• Positive Sentiment: Analyst optimism and price‑target lifts — multiple firms raised targets (notably Mizuho to $310, Wells Fargo to $255, Baird and others), and coverage remains skewed positive, which can support upside momentum and bid interest. Read More.
• Neutral Sentiment: Management outreach scheduled — Axsome will participate in May investor conferences (including a BofA fireside chat), offering additional investor access but uncertain immediate impact. Read More.
• Neutral Sentiment: Earnings detail and call transcript available — analysts are parsing the conference call and guidance implications; deeper read may resolve questions around sales cadence and expense trajectory. Read More.
• Negative Sentiment: Profitability miss — GAAP EPS of ($1.26) missed consensus (~$0.85 loss), and negative margins/ROE highlight near‑term profitability and cost structure concerns despite revenue strength. Read More.
• Negative Sentiment: Insider selling — COO Mark Jacobson disclosed sales (large blocks on May 4 and a smaller sale May 5), which may raise short‑term sentiment questions even though filers report remaining holdings. Read More.
• Negative Sentiment: Durability concerns — some analysts/commentators question sequential product sales trends and achievability of peak revenue assumptions, which could temper multiple expansion absent clearer margin improvements. Read More.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after purchasing an additional 235,626 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after purchasing an additional 472,422 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Axsome Therapeutics by 84.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after purchasing an additional 609,516 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Axsome Therapeutics by 28.6% during the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after purchasing an additional 282,937 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Axsome Therapeutics by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock valued at $184,544,000 after purchasing an additional 12,549 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AXSM shares. Wolfe Research started coverage on shares of Axsome Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $230.00 price objective on the stock. TD Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, May 1st. Needham & Company LLC raised their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday. Finally, Royal Bank Of Canada raised their price objective on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $251.26.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.